Neurotrope |
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-4,ajax_fade,page_not_loaded,,select-theme-ver-4.4,wpb-js-composer js-comp-ver-5.4.7,vc_responsive


Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes various treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s Disease, Fragile X Syndrome and Niemann-Pick Type C.


Neurotrope has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1 stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.

Studies have demonstrated that PKCϵ plays a pivotal role in learning and memory. Bryostatin, a small molecule, penetrates the blood-brain barrier and activates PKCϵ, resulting in improved synaptic function, new synapse formation, repair of damaged synapses, and prevention of neuronal death. Neurotrope’s preclinical work demonstrates improved memory and learning in multiple Alzheimer’s mouse models and several other animal models.


Alzheimer’s disease is the most common form of dementia, accounting for 60%-80% of all cases. Neurotrope has conducted the first placebo-controlled, Phase 2 trial of a protein kinase C epsilon (PKCɛ) activator for the treatment of Alzheimer’s, which in preclinical studies induced the growth of new synapses and prevented neuronal death. Recent clinical trial data showed sustained increase in Severe Impairment Battery measures and improvement in cognition, suggesting the drug may treat the progression of AD, rather than just symptoms. A confirmatory trial will commence in 2018.


Fragile X syndrome is a genetic disorder that causes developmental delays, intellectual and learning disabilities, anxiety, and autism spectrum disorders. FXS affects 135,000 in the U.S. alone. Bryostatin-1 for Fragile X has been designated as an orphan drug, and in animal models, was shown to restore synaptic networks, rectify memory deficits, and reverse biochemical abnormalities. Neurotrope preclinical data, in a collaboration with the FRAXA Research Foundation, showed that Bryostatin-1 significantly improves autism spectrum abnormalities. Neurotrope plans to initiate clinical testing of FXS patients in 2018.


Niemann Pick Type C is both a debilitating and lethal disease, affecting about 35,000 children per year. Neurotrope is working with world renowned experts at the Icahn School of Medicine, Mt. Sinai to develop its lead compound, Bryostatin-1, as a potential treatment for the excessive accumulation of cholesterol and other lipids in the viscera and brain resulting in cell death and to neuologic symptoms, including difficulty in swallowing and speaking, loss of coordination, seizures, and progressive dementia. There is no FDA approved treatment for Niemann-Pick Type C.

Key PublicationsDownload
The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades
PKC epsilon Promotes Synaptogenesis through Membrane Accumulation of the Postsynaptic Density Protein PSD-95 J Biol Chem. 5;291(32):16462-76, 2016 Abhik Sen, Jarin Hongpaisan, Desheng Wang, Thomas J. Nelson and Daniel L. Alkon
Rescue of Synaptic Phenotypes and Spatial Memory in Young Fragile X Mice. J. Pharmacol. Exp. Ther. 357: 300-310, 2016Miao-Kun Sun, Jarin Hongpaisan, and Daniel L. Alkon
ApoE4 and Aβ Oligomers Reduce BDNF Expression via HDAC Nuclear Translocation Neuroscience 35(19): 7538-7551; doi: 10.1523 /JNEUROSCI. 0260-15.2015 Abhik Sen, Thomas J. Nelson and Daniel L. Alkon
Apolipoprotein E3 (ApoE3) but Not ApoE4 Protects against Synaptic Loss through Increased Expression of Protein Kinase Cε. J Biol Chem 287(19), 15947-15948, 2012. Sen A, Alkon DL, Nelson TJ
PKCε Activation Prevents Synaptic Loss, Aβ Elevation, and Cognitive Deficits in Alzheimer's Disease Transgenic Mice, Journal of Neuroscience, 31(2):630–643, 2011. Hongpaisan, J., Sun, MK, Alkon DL
Postischemic PKC activation rescues retrograde and anterograde long-term memory. (Proc Nat. Acad. Sci. USA) 106 (34): 14676–14680, 2009. Sun, MK, Hongpaisan, J, Alkon, DL
A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci USA 104 (49): 19571-19576, 2007. Hongpaisan J, and Alkon DL
Towards universal therapeutics for memory disorders. Trends in Pharmacological Sciences, June 2015, Vol. 36, No. 6. Miao-Kun Sun, Thomas J. Nelson, and Daniel L. Alkon
PKC activator therapeutic for mild traumatic brain injury in mice. Neurobiology of Disease 41 (2011) 329–337. Ofer Zohar, Rotem Lavy, Xiaomei Zi, Thomas J. Nelson, Jarin Hongpaisan, Chaim G. Pick, D.L. Alkon


Neurotrope is building a sustainable pipeline of treatments in major areas of unmet need.


Neurotrope is led by an experienced team with deep expertise in neurodegenerative disorders and successful track records in both drug discovery and development.

Charles Ryan, J.D., Ph.D.
Chief Executive Officer

Daniel Alkon, M.D.
President & Chief Science Officer

Robert Weinstein
Chief Financial Officer

Elaine Grenier
Executive Director, Clinical Ops

Alan Tuchman, M.D.
Acting Chief Medical Officer

Joshua Silverman


View ›

William Singer

Vice Chairman

View ›

Charles Ryan, J.D., Ph.D.

Director & CEO

View ›

Jonathan Schechter.


View ›

Bruce Bernstein


View ›

George Perry, Ph.D.


View ›

Ivan Gergel, M.D.


View ›

Martin R. Farlow

(Chairman) MS

View ›

Paul Coleman, PhD

View ›

Daniel F. Hanley Jr. MD

View ›

Marwan Sabbagh, MD

View ›

Lee Jen Wei, PhD

View ›



New York Office

1185 Avenue of the Americas, 3rd Floor
New York, NY 10036
(973) 242-0005

Princeton Office

112 Nassau Street
Princeton, NJ 08540
(973) 500-6756

Robert Weinstein
Chief Financial Officer
(973) 242-0005×101